Kirsten Gillibrand actually said...

"So if you find that degradation was higher than you expected, will you then go back and challenge other assumptions you made in the review for relicensing?"

"I think it is very unwise and I think it is unsafe."

"Their technical evaluation concerning Unit 2 was flawed, so I would be highly concerned that their technical evaluation concerning Unit 3 is also flawed."

"When Turing Pharmaceuticals was establishing its pricing plan for the drug Daraprim, you raised concerns internally about the proposed price increase."